RT @RichardPAConway: Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabr
Tweet Content
Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L
Links
EULAR Abstract Archive
http://scientific.sparx-ip.net/archiveeular/index.cfm?c=a&searchfor=LB0005&view…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off